To further evaluate the relationship between OSBPL3 and tumor progression (relapse/metastasis), we confirmed the PFI (Figure 5A) and DFI (Supplementary Figure S5A), and the data showed highly expressed OSBPL3 was linked to poor PFI and DFI for both LGG and PAAD cancers and poor PFI for LIHC, MESO, PCPG, PRAD, TGCT, and UVM cancers (all p < 0.05). Here, OSBPL3 is linked to neoplasm.